Fairmount Funds Management LLC Global Blood Therapeutics, Inc. Transaction History

Fairmount Funds Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.3 - $37.39 $5.1 Million - $8.56 Million	-228,911 Reduced 19.36%	953,396 $30.5 Million
Q1 2022 May 16, 2022	BUY	$25.68 - $35.59 $11.3 Million - $15.6 Million	439,307 Added 59.13%	1,182,307 $41 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $12.3 Million - $19.8 Million	493,000 Added 197.2%	743,000 $21.7 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $1.02 Million - $1.49 Million	40,000 Added 19.05%	250,000 $6.37 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $1.14 Million - $1.52 Million	35,000 Added 20.0%	210,000 $7.35 Million
Q1 2021 May 14, 2021	SELL	$38.94 - $50.85 $1.56 Million - $2.03 Million	-40,000 Reduced 18.6%	175,000 $7.13 Million
Q4 2020 Feb 12, 2021	BUY	$37.65 - $63.77 $8.09 Million - $13.7 Million	215,000 New	215,000 $9.31 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.